10/08/2026 MoonLake announced Phase 3 results of Sonelokimab in Psoriatic Arthritis MoonLake announced Phase 3 results of Sonelokimab in Psoriatic Arthritis (Ref) MoonLake Immunotherapeutics announced positive topline results from the Phase 3, IZAR-1/ NCT06641076 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis (PsA). The trial met all the clinical endpoint at week 16 for 60 mg sonelokimab with induction. The primary endpoint of ACR50 was

22/02/2026 MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis MoonLake announced topline results from its Phase 2 study of sonelokimab in axial spondyloarthritis ( Ref ) MoonLake Immunotherapeutics announced positive topline results from its Phase 2, S-OLARIS study evaluating sonelokimab (IL-17A and IL-17F inhibitor) in patients with radiographic and non-radiographic axial spondyloarthritis The study demonstrated a clinically m